Shandong Boan Biotech Co., Ltd. (6955)

Overview

Shandong Boan Biotechnology Co., Ltd. is at the forefront of biotechnology innovation, focusing on the development, manufacture, and commercialization of biologics for a global audience from its headquarters in Yantai, China. Since its inception in 2013, the company has made significant strides in addressing some of the most pressing medical challenges. With a commitment to improving patient outcomes, Shandong Boan Biotechnology has become a key player in the pharmaceutical industry, particularly in the People's Republic of China and abroad. As a subsidiary of Shandong Luye Pharmaceutical Co., Ltd., it leverages extensive research and development capabilities to create groundbreaking therapies for various diseases, including cancer, osteoporosis, and infectious diseases such as COVID-19.

Products and Services

• Boyounuo (BA1101) bevacizumab injection

  This product is utilized for the treatment of several types of cancer, including metastatic or recurrent non-small cell lung cancer (NSCLC), advanced recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer, showcasing the company's commitment to battling cancer.

• Boyoubei (BA6101)

  A human immunoglobulin G2 monoclonal antibody designed for treating postmenopausal women with osteoporosis at a high risk for fracture, indicating the company's focus on bone health and the prevention of fractures.

• BA1102 denosumab injection

  Currently in development, this product is aimed at treating patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as giant cell tumor of the bone (GCTB), expanding the company's oncology pipeline.

• LY-CovMab

  A promising treatment for COVID-19, demonstrating Shandong Boan Biotechnology's versatility and quick response to global health emergencies.

• BA9101 aflibercept intraocular injection

  Targeting a range of eye diseases, this product is designed for patients with wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, diabetic retinopathy, and retinopathy of prematurity, indicating the company's commitment to combating vision loss.

• Other oncology and diabetes treatments

  The development portfolio further includes BA1104 for various cancers, BA5101 for type 2 diabetes, and a range of other promising biologics such as BA1105, BA1201, BA1106, BA1202, BA1301, and BA2101, highlighting the company's extensive research in medical biotechnology aiming to address a wide spectrum of diseases with innovative therapies.